Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FHD-286 · 2 trials · 8 indications
ORR is the percentage of participants achieving complete or partial response on treatment based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).
| Arm | Type | Description |
|---|---|---|
| FHD-286 | EXPERIMENTAL | * Baseline visit * Cycle 1 through End of Treatment (21-day cycles) * Days 1 - 21: Predetermined dose of FHD-286 1X daily. Possible dose escalation or based on tolerability. * 30 day follow up post-treatment discontinuation * Annual follow up for up to 5 years. |
| FHD-286 Monotherapy | EXPERIMENTAL | Closed to Enrollment |
| FHD-286 in Combination with LDAC | EXPERIMENTAL | FHD-286 administered orally + LDAC administered subcutaneously |
| FHD-286 in Combination with Decitabine | EXPERIMENTAL | FHD-286 administered orally + decitabine administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| FHD-286 | DRUG | SMARCA4/2 inhibitor, capsule, taken orally per protocol |
| Low Dose Cytarabine | DRUG | LDAC administered subcutaneously (SC) |
| Decitabine | DRUG | Decitabine administered intravenously |
Inclusion Criteria: * Adult age l8 years or older, who have provided written informed consent. * Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor. * Positive \>50%...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Tarlatamab |
FHD-286 is an investigational small molecule being developed for advanced hematologic malignancies and small cell lung cancer. In hematologic malignancies, it is studied in relapsed or refractory acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia. It is also being evaluated in POU2F3-positive small cell lung cancer.
FHD-286 targets SMARCA2 and SMARCA4, which are catalytic subunits of the SWI/SNF chromatin remodeling complex. By inhibiting these targets, FHD-286 aims to disrupt gene expression programs that drive cancer cell growth in certain malignancies.
FHD-286 is being developed by Foghorn Therapeutics Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol FHTX. The company is conducting clinical trials of FHD-286 in advanced hematologic malignancies and small cell lung cancer.
FHD-286 is in Phase 1 clinical development. One Phase 1 trial is active but not recruiting patients with advanced hematologic malignancies. A separate Phase 2 trial in small cell lung cancer is not yet recruiting. FHD-286 is investigational and has not been approved by regulatory authorities.
FHD-286 is being studied in two clinical trials. NCT04891757 is a Phase 1 trial in advanced hematologic malignancies with 144 participants, active but not recruiting. NCT07551635 is a Phase 2 trial in POU2F3-positive small cell lung cancer with 20 participants, not yet recruiting. Both trials are in the United States.